Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

In the Spotlight

  • In the Spotlight
    Remote Controlled CARs: Towards a Safer Therapy for Leukemia
    Carl H. June
    Cancer Immunol Res August 1 2016 4 (8) 643-643; DOI:10.1158/2326-6066.CIR-16-0132

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia
    Hiroshi Ureshino, Takero Shindo, Hiroyoshi Nishikawa, Nobukazu Watanabe, Eri Watanabe, Natsuko Satoh, Kazutaka Kitaura, Hiroaki Kitamura, Kazuko Doi, Kotaro Nagase, Hiromi Kimura, Makoto Samukawa, Susumu Kusunoki, Masaharu Miyahara, Tadasu Shin-I, Ryuji Suzuki, Shimon Sakaguchi and Shinya Kimura
    Cancer Immunol Res August 1 2016 4 (8) 644-649; DOI:10.1158/2326-6066.CIR-15-0303

    Anti-CCR4 treatment of ATL destroys leukemic and normal Tregs, which can lead to autoimmunity. Only leukemic Tregs expressed CADM1, distinguishing the two populations. Treg depletion was associated with autoimmunity and Treg reemergence with relapse of ATL.

Priority Brief

  • Priority Brief | AuthorChoice
    Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade
    Michael J. McNamara, Ian Hilgart-Martiszus, Diego M. Barragan Echenique, Stefanie N. Linch, Melissa J. Kasiewicz and William L. Redmond
    Cancer Immunol Res August 1 2016 4 (8) 650-657; DOI:10.1158/2326-6066.CIR-16-0022

    PD-1/CTLA-4 dual blockade has shown substantial promise against refractory tumors in some patients. Biomarkers were sought to identify patients early in treatment who are responding positively. Strong production of IFNγ shortly after treatment commenced significantly correlated with survival.

Research Articles

  • Research Articles
    A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration
    Reona Sakemura, Seitaro Terakura, Keisuke Watanabe, Jakrawadee Julamanee, Erina Takagi, Kotaro Miyao, Daisuke Koyama, Tatsunori Goto, Ryo Hanajiri, Tetsuya Nishida, Makoto Murata and Hitoshi Kiyoi
    Cancer Immunol Res August 1 2016 4 (8) 658-668; DOI:10.1158/2326-6066.CIR-16-0043

    On-target/off-tumor effects can be problematic if the antigen target for CAR T-cell therapy is also expressed on normal tissue. An inducible CAR expression strategy was used that controlled CAR expression and shows promise in discriminating between tumor and B-cell expression of CD19.

  • Research Articles
    Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens
    Todd D. Prickett, Jessica S. Crystal, Cyrille J. Cohen, Anna Pasetto, Maria R. Parkhurst, Jared J. Gartner, Xin Yao, Rong Wang, Alena Gros, Yong F. Li, Mona El-Gamil, Kasia Trebska-McGowan, Steven A. Rosenberg and Paul F. Robbins
    Cancer Immunol Res August 1 2016 4 (8) 669-678; DOI:10.1158/2326-6066.CIR-15-0215

    On-target/off-tumor effects can be problematic if the antigen target for CAR T-cell therapy is also expressed on normal tissue. An inducible CAR expression strategy was used that controlled CAR expression and shows promise in discriminating between tumor and B-cell expression of CD19.

  • Research Articles
    Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes
    Vishwajith Sridharan, Evisa Gjini, Xiaoyun Liao, Nicole G. Chau, Robert I. Haddad, Mariano Severgnini, Peter Hammerman, Adel El-Naggar, Gordon J. Freeman, F. Stephen Hodi, Scott J. Rodig, Glenn Dranoff and Jonathan D. Schoenfeld
    Cancer Immunol Res August 1 2016 4 (8) 679-687; DOI:10.1158/2326-6066.CIR-16-0031

    PD-1 ligand expression and T-cell infiltration may predict responsiveness to PD-1 pathway inhibitors. ACC tumors expressed PD-L2 and the Wnt and PI3K pathways but had little immune infiltration. Chemoradiotherapy promoted antitumor responses, suggesting potential synergies with PD-1 blockade.

  • Research Articles
    HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment
    Maya Zigler, Alexei Shir, Salim Joubran, Anna Sagalov, Shoshana Klein, Nufar Edinger, Jeffrey Lau, Shang-Fan Yu, Gabriel Mizraji, Anat Globerson Levin, Mark X. Sliwkowski and Alexander Levitzki
    Cancer Immunol Res August 1 2016 4 (8) 688-697; DOI:10.1158/2326-6066.CIR-15-0203

    HER2 is overexpressed in many breast tumors. A therapy was developed that targeted pIC (a TLR3 ligand) to HER2-positive tumors. Tumor growth was significantly inhibited, and antitumor immunity was activated via multiple signaling pathways.

  • Research Articles
    Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells
    Rebekah L. Browning, William H. Byrd, Nikhil Gupta, Jeffrey Jones, Xiaokui Mo, Erin Hertlein, Lianbo Yu, Natarajan Muthusamy and John C. Byrd
    Cancer Immunol Res August 1 2016 4 (8) 698-707; DOI:10.1158/2326-6066.CIR-15-0291

    Lenalidomide is a potential therapy for patients with CLL. It induces IL21 production by T cells while increasing IL21 receptors on CLL B cells, with concomitant cytotoxicity to CLL B cells, operating through multiple mechanisms.

  • Research Articles
    Cross-talk between 4-1BB and TLR1–TLR2 Signaling in CD8+ T Cells Regulates TLR2′s Costimulatory Effects
    Ann Mary Joseph, Ratika Srivastava, Jovanny Zabaleta and Eduardo Davila
    Cancer Immunol Res August 1 2016 4 (8) 708-716; DOI:10.1158/2326-6066.CIR-15-0173

    The mechanisms underlying the costimulatory effects of TLR2 engagement on T cells are poorly understood. Costimulatory TLR1–TLR2 signaling in CD8+ T cells was found to be largely mediated by 4-1BB and contributes to mounting an antitumor immune response.

Back to top
PreviousNext
Cancer Immunology Research: 4 (8)
August 2016
Volume 4, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Jump to

  • In the Spotlight
  • Cancer Immunology Miniatures
  • Priority Brief
  • Research Articles
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Characterization of Murine Syngeneic Tumor Models
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement